Tharimmune, Inc. (NASDAQ:THAR) Short Interest Up 37.4% in December

Tharimmune, Inc. (NASDAQ:THAR) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 89,300 shares, an increase of 37.4% from the November 30th total of 65,000 shares. Currently, 6.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is currently 0.1 days.

Tharimmune Price Performance

Shares of THAR stock traded down $0.09 during mid-day trading on Friday, hitting $2.06. The company had a trading volume of 144,086 shares, compared to its average volume of 348,641. The stock’s 50 day moving average price is $2.29 and its 200-day moving average price is $2.72. Tharimmune has a 52-week low of $1.84 and a 52-week high of $8.42.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC bought a new position in Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw began coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 target price for the company.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).